# Cognition Therapeutics Is Targeting A Critical Form Of Dementia

By Johnny Rice, Benzinga

![](https://public.newsdirect.com/843707967/9NdiNlRu.png)

Lisa Ricciardi, president and CEO of Cognition Therapeutics (NASDAQ: CGTX) was recently a guest on Benzinga’s All-Access.

Cognition Therapeutics is a neuroscience company that is developing oral medications to treat neurodegenerative disorders, with recent breakthroughs in the treatment of dementia with Lewy bodies (DLB) and Alzheimer’s.

The company says its drug candidate, CT1812, showed very promising results from its recently completed phase 2 trial. The drug will now progress to phase 3.

Watch the full interview here:

Featured photo by Rod Long on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Contact DetailsBenzinga

+1 877-440-9464

info@benzinga.com

Company Websitehttp://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/cognition-therapeutics-is-targeting-a-critical-form-of-dementia-843707967 

---

[Original/Source Press Release](https://newsdirect.com/news/cognition-therapeutics-is-targeting-a-critical-form-of-dementia-843707967)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cognition-therapeutics-advances-drug-candidate-ct1812-to-phase-3-after-promising-phase-2-results/671a6926df23b18aa9fa62bfd070cc74) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1i0e7kh/cognition_therapeutics_advances_drug_candidate/) 



![Blockchain Registration](https://cdn.newsramp.app/news-direct/qrcode/251/13/isle_CYu.webp)